XVIVO: Some points ahead of Q3 - Redeye

XVIVO’s Q3 comes after the SEK 440m directed share issue and before launching the US Heart study. We expect XVIVVO also to initiate a US study for Liver Assist. XVIVO had a strong Q3 result in 2022, and we look forward to the Q3 result and a trading update on 24 October.

Länk till analysen i sin helhet: https://www.redeye.se/research/948601/xvivo-some-points-ahead-of-q3?utm_source=finwire&utm_medium=RSS